KARLENE MULLINS: Open Payments
NPI 1811482037 · MC DONALD, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$751 in 27 payments from 13 companies in 2025. Trend: 2023 $234 · 2024 $111 · 2025 $751
Food & beverage: $751
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $218 |
| GENZYME CORPORATION | 6 | $201 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $82 |
| Optinose US, Inc. | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Cycle Pharmaceuticals Inc | 1 | $29 |
| Genentech USA, Inc. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $27 |
| BioCryst US Sales Co., LLC | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
Products named: DUPIXENT, FASENRA, NEFFY, Xhance, Sajazir, Xolair, Veozah, ORLADEYO.
Industry payments across TN — which companies pay providers there.
